Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2014Open Access

Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMarius IliéCentre National de la Recherche ScientifiqueVHVéronique HofmanCentre National de la Recherche ScientifiqueÉLÉlodie Long-MiraCentre Hospitalier Universitaire de Nice

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ilié et al. (2014) studied this question.

synapsesocial.com/papers/6a1068b710ed65f1d0fccb04https://doi.org/10.3978/j.issn.2305-5839.2014.08.11
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Detection of Mutations in EGFR in Circulating Lung-Cancer Cells2008 · 1,618 citations
  2. 2Cytopathologic Detection of Circulating Tumor Cells Using the Isolation by Size of Epithelial Tumor Cell Method2010 · 127 citations
  3. 3Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition2012 · 573 citations
  4. 4Liquid Biopsies: Genotyping Circulating Tumor DNA2014 · 2,245 citations